Uniwersytecki Szpital Kliniczny W Opolu
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Uniwersytecki Szpital Kliniczny W Opolu, clinical research in cardiovascular diseases focuses on serious heart conditions such as acute myocardial infarction and cardiogenic shock. The studies are designed to assess whether new treatments can improve blood pressure, support heart recovery, and enhance care after a heart attack.
- Evaluating a potential therapy for acute myocardial infarction
- Testing treatment options for cardiogenic shock
- Assessing safety, tolerability, and treatment effectiveness in acute cardiac care
This work reflects a strong focus on urgent cardiology needs, with the goal of improving outcomes for patients facing life-threatening heart-related events.
Skin and Connective Tissue Diseases
Research in skin and connective tissue diseases at this site includes studies in chronic spontaneous urticaria, a condition that can cause persistent itching and hives. The trials are aimed at evaluating new therapies that may help control symptoms and improve daily comfort for affected adults.
- Studying treatment options for chronic spontaneous urticaria
- Assessing symptom relief and overall effectiveness of a new therapy
- Exploring better ways to manage long-term allergic skin disease
This area highlights the hospital’s broader interest in both dermatologic and inflammatory conditions, with research centered on improving patient well-being through more effective care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 13 therapeutic areas and 15 of 73 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 70 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 24 by active trials.
- 1Agencja Badań Medycznych3active
lock +23 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Agencja Badań Medycznych4trials
lock +11 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny W Opolu
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Budiodarone in Subjects with Non-permanent Atrial Fibrillation | Xyra LLC | Phase IV | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 73 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Barzolvolimab | 4 | Unknown | 2022-11-09 | 2026-04-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.